Novo Nordisk A/S (NOV.DE) Stock Analysis & Winston Score

Novo Nordisk is a Danish pharmaceutical company that makes medicines for people with diabetes and obesity. Its most well-known products are insulin treatments and the GLP-1 drugs Ozempic and Wegovy, which help control blood sugar and reduce body weight. It is one of the largest makers of diabetes medicines in the world and supplies hospitals, pharmacies, and patients across more than 170 countries. The company earns money by selling prescription drugs directly to healthcare systems, insurers, and pharmacies. Most of its revenue comes from the United States and Europe, and its deep expertise in GLP-1 science, along with decades of manufacturing experience, gives it a strong competitive position that is hard for rivals to quickly copy. The key growth driver is expanding use of GLP-1 drugs for obesity treatment, though the main risk is pricing pressure from governments and insurers, plus growing competition from other drugmakers developing similar medicines.